Increase of E-cigarette Use during Teenage Pregnancy

Industry Insight by 2FIRSTS.ai
Dec.15.2023
Increase of E-cigarette Use during Teenage Pregnancy
Teenage e-cigarette use during pregnancy has risen from 0.8% in 2016 to 4.1% in 2021, according to a study.

According to a study published online on December 13th in JAMA Network Open, the prevalence of e-cigarette use in late pregnancy among adolescents in the United States has increased from 0.8% in 2016 to 4.1% in 2021.

 

Researchers primarily analyzed data from the 2016-2021 Pregnancy Risk Assessment Monitoring System. They specifically focused on 10,428 teenagers aged 10-19 who had previously given birth to a singleton and provided information on their use of e-cigarettes or conventional cigarettes.

 

Although researchers found that the prevalence of exclusive e-cigarette use has increased by approximately five-fold, the percentage of pregnant women who only use conventional cigarettes has decreased from 9.2% in 2017 to 3.2% in 2021. The proportion of pregnant women who use both e-cigarettes and conventional cigarettes fluctuated between 0.6% and 1.6%.

 

There was no significant difference in the proportion of low birth weight among non-smoking or non-e-cigarette using adolescents (12.9%), e-cigarette only users (16.8%), or adolescents who used both cigarettes and e-cigarettes (17.6%). However, researchers found a significant association between smoking only and the proportion of low birth weight (24.6%).

 

In this study, Dr. Xiaozhong Wen, corresponding author from the Jacobs School of Medicine and Biomedical Sciences at the State University of New York, Buffalo, stated:

 

In our analysis, using only e-cigarettes and using both traditional cigarettes and e-cigarettes simultaneously appears to have no significant statistical association with lower birth weight. However, considering the lower prevalence of usage and limited sample size, this finding should be interpreted with caution.

 

The limitations of this study lie in the possibility that participants may underreport their use of e-cigarettes and traditional cigarettes out of concern for social stigma. Additionally, researchers lack information on the use of e-cigarettes during the first and second trimesters of pregnancy, exposure to secondhand smoke, marijuana use, and dietary habits.

 

This study was supported by the National Institute on Drug Abuse, the Center for Tobacco Products of the Food and Drug Administration, the National Heart, Lung, and Blood Institute, as well as the American Heart Association. One of the co-authors of the study has received grants from Pfizer Inc. and personal fees from Johnson & Johnson, the World Health Organization, and the Campaign for Tobacco-Free Kids.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.
Feb.03 by 2FIRSTS.ai
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
Tamarind Intelligence’s decision to appoint a technology-sector executive as chief executive officer signals more than a leadership reshuffle at a specialist data firm. It reflects a broader structural shift across the global nicotine industry, where companies, regulators and intelligence providers are embedding artificial intelligence into core operations.
Special Report
Feb.18
Coalition pushes back on Hochul’s proposed 75% wholesale tax on alternative nicotine products
Coalition pushes back on Hochul’s proposed 75% wholesale tax on alternative nicotine products
A coalition of business owners and former law enforcement officers protested Gov. Kathy Hochul’s proposed 75% wholesale tax on alternative nicotine products, saying it would fuel organized crime and burden low-income New Yorkers, while supporters said it would curb addiction and help fund hospitals.
Feb.28 by 2FIRSTS.ai
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
The U.S. International Trade Commission (ITC) has terminated Investigation 337-TA-1410 after invalidating key vape patent claims asserted by R.J. Reynolds Vapor Company, removing the immediate risk of import bans for dozens of companies. However, a new case—337-TA-1486—has already opened a more consequential legal front, shifting the focus from patent disputes to regulatory compliance across the vape supply chain, including PACT Act reporting, tax compliance, and FDA marketing authorization.
BAT
Mar.11